podcast.de
Anmeldung
Anmeldung Registrierung
Auto Hell Dunkel
Erweiterte Suche
  1. Startseite
  2. Podcasts
  3. Medizin - Open Access LMU - Teil 17/22 Podcast
  4. Treatment of Advanced Emphysema with Emphysematous Lung Sealant (AeriSeal (R))
Background: This report summarizes initial tests of an
emphysematous lung synthetic polymer sealant (ELS) designed to
reduce lung volume in patients with advanced emphysema. Objectives:
The primary study objective was to define a therapeutic strategy to
optimize treatment safety and effectiveness. Methods: ELS therapy
was administered bronchoscopically to 25 patients with
heterogeneous emphysema in an open-label, noncontrolled study at 6
centers in Germany. Treatment was performed initially at 2-4
subsegments. After 12 weeks, patients were eligible for repeat
therapy to a total of 6 sites. Safety and efficacy were assessed
after 6 months. Responses were evaluated in terms of changes from
baseline in lung physiology, functional capacity, and
health-related quality of life. Follow-up is available for 21 of 25
patients. Results: Treatment was well tolerated. There were no
treatment-related deaths (i.e. within 90 days of treatment), and an
acceptable short-and long-term safety profile. Physiological and
clinical benefits were observed at 24 weeks. Efficacy responses
were better among Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stage III patients {[}n = 14; change in residual
volume/total lung capacity (Delta RV/TLC) = -7.4 +/- 10.3%; Delta
forced expiratory volume in 1 s (Delta FEV(1)) = +15.9 +/- 22.6%;
change in forced vital capacity (Delta FVC) = +24.1 +/- 22.7%;
change in carbon monoxide lung diffusion capacity (Delta DLCO) =
+19.3 +/- 34.8%; change in 6-min walk test (Delta 6MWD) = +28.7 +/-
59.6 m; change in Medical Research Council Dyspnea (Delta MRCD)
score = -1.0 +/- 1.04 units; change in St. George's Respiratory
Questionnaire (Delta SGRQ) score = -9.9 +/- 15.3 units] than for
GOLD stage IV patients (n = 7; Delta RV/TLC = -0.5 +/- 6.4%; Delta
FEV 1 = +2.3 +/- 12.3%; Delta FVC = +2.6 +/- 21.1%; Delta DLCO =
-2.8 +/- 17.2%; Delta 6MWD = +28.3 +/- 58.4 m; Delta MRCD = 0.3 +/-
0.81 units; Delta SGRQ = -6.7 +/- 7.0 units). Conclusions: ELS
therapy shows promise for treating patients with advanced
heterogeneous emphysema. Additional studies to assess responses in
a larger cohort with a longer follow-up are warranted. Copyright
(C) 2011 S. Karger AG, Basel

Weitere Episoden

Analysis of IL2/IL21 Gene Variants in Cholestatic Liver Diseases Reveals an Association with Primary Sclerosing Cholangitis

Analysis of IL2/IL21 Gene Variants in Cholestatic Liver Diseases Reveals an Association with Primary Sclerosing Cholangitis

vor 15 Jahren
Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man

Biliary Bicarbonate Secretion Constitutes a Protective Mechanism against Bile Acid-Induced Injury in Man

vor 15 Jahren
Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life

Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life

vor 15 Jahren
Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

Growth Patterns in the First Three Years of Life in Children with Classical Congenital Adrenal Hyperplasia Diagnosed by Newborn Screening and Treated with Low Doses of Hydrocortisone

vor 15 Jahren
Missing Heritability in the Tails of Quantitative Traits? A Simulation Study on the Impact of Slightly Altered True Genetic Models

Missing Heritability in the Tails of Quantitative Traits? A Simulation Study on the Impact of Slightly Altered True Genetic Models

vor 15 Jahren
Alle Episoden anzeigen
In Podcasts werben
Schalte jetzt Werbung in Podcasts.
Episode melden

„Treatment of Advanced Emphysema with Emphysematous Lung Sealant (AeriSeal (R))“

Worum geht es? Danach fragen wir noch nach dem Grund.

Abonnenten

Er
Erasmus2

Teilen

Mein Archiv

Deine Privatkopie der Folgen, die du nicht verlieren willst.

Podcast-Folgen verschwinden. Feeds werden auf die letzten Episoden gekürzt, Hoster räumen alte Dateien ab, Formate wechseln den Anbieter und lassen ihr Archiv zurück. Mit „Mein Archiv“ sichert podcast.de die Folgen deiner Podcasts für dich — angefangen bei den ältesten, denn die sind zuerst weg.

  • Deine gesicherten Folgen bleiben hörbar, auch wenn das Original offline geht.
  • Auch Folgen, die im heutigen Feed gar nicht mehr stehen — podcast.de kennt sie noch.
  • Herunterladen bleibt möglich, solange die Folge beim Podcaster liegt. Der zählt seine Abrufe wie bisher.
Startet bald

Sei beim Start von Mein Archiv dabei

Mein Archiv ist fast fertig. Trag dich ein, dann bekommst du eine E-Mail, sobald es losgeht – und bist von Anfang an dabei. Wir schreiben dir nur zum Start, keine Werbung, keine Weitergabe deiner Daten.

Du bekommst zuerst eine Bestätigungsmail. Abmelden geht jederzeit. Datenschutz